Cytrellis CEO Denise Dajles Disrupts Medical Aesthetics With Ellacor Device

Cytrellis Biosystems CEO Denise Dajles is successfully steering her company to capture a massive new gap in the medical aesthetics market. Driven by the explosive rise of weight-loss medications, millions of patients are seeking solutions for severe skin laxity. To meet this demand, Dajles is scaling the commercial distribution of ellacor, a pioneering, non-surgical skin-removal device. The breakthrough technology offers a middle ground for individuals who require more intensive results than energy-based skin tightening can provide but want to avoid invasive plastic surgery.

The GLP-1 Weight Loss Wave Reshapes Patient Demand

The primary catalyst for Cytrellis’s rapid commercial growth is the mainstream adoption of GLP-1 medications like Ozempic and Wegovy, currently utilized by over 12% of American adults. While these treatments help individuals shed substantial weight, patients are frequently left with excessive loose skin across the face, abdomen, and knees. Ellacor addresses this dilemma by utilizing proprietary Micro-Coring Technology. The specialized device uses hollow needles to physically remove micro-portions of excess tissue, triggering the body’s natural healing response to create tighter skin without leaving surgical scars.

Global Expansion Built on Scientific Rigor

Building an entirely new product category within the aesthetics industry requires strict discipline and medical transparency. To combat skepticism, Dajles has anchored the company’s marketing strategy entirely in peer-reviewed clinical studies rather than relying on hyperbole or artificial intelligence-generated alterations. This evidence-based approach has accelerated global adoption among medical practitioners. Cytrellis has successfully expanded its commercial footprint outside the United States, securing a solid international presence across Canada, South Korea, Japan, South Africa, Saudi Arabia, and the United Arab Emirates.